Celera, deCode, Perlegen deal

Perlegen granted Celera a non-exclusive, worldwide license to its predictive biomarkers of coronary heart disease and IP covering methods of genetic analysis to detect variants on chromosome 9p21 associated with risk of cardiovascular disease, especially in diabetic patients. Celera will use the technology to provide testing services and to develop test kits for managing patients with cardiovascular disease and diabetes. Perlegen will receive an undisclosed upfront payment and is eligible for royalties. ...